Why Choose Us?
0% AI Guarantee
Human-written only.
24/7 Support
Anytime, anywhere.
Plagiarism Free
100% Original.
Expert Tutors
Masters & PhDs.
100% Confidential
Your privacy matters.
On-Time Delivery
Never miss a deadline.
University of Illinois, Chicago NURS 531 Chapter 23: Atherosclerosis and lipoprotein metabolism MULTIPLE CHOICE 1)Activation of the peroxisome proliferator-activated receptor-alpha is produced by administration of ezetimibe fenofibrate simvastatin niacin colesevelam 2
University of Illinois, Chicago
NURS 531
Chapter 23: Atherosclerosis and lipoprotein metabolism MULTIPLE CHOICE
1)Activation of the peroxisome proliferator-activated receptor-alpha is produced by administration of
- ezetimibe
- fenofibrate
- simvastatin
- niacin
- colesevelam
2. Ezetimibe reduces serum LDL-cholesterol levels by
- inhibiting cholesterol synthesis
- increasing HDL-cholesterol levels
- inhibiting cholesterol absorption
- inhibiting bile acid reabsorption
- stimulate lipoprotein lipase
3. Myositis leading to rhabdomyolysis is a potentially severe adverse effect of
- atorvastatin
- niacin
- colestipol
- ezetimibe
- cholestyramine
4. Increased expression of apoproteins A-I and A-II occurs in persons receiving
- colestipol
- niacin
- simvastatin
- ezetimibe
- gemfibrozil
5. Simvastatin and related drugs have been shown to reduce mortality in persons with
- hypertriglyceridemia
- low HDL-cholesterol levels
- an inability to make LDL receptors
- symptomatic coronary artery disease
- myositis
6. Which drug inhibits hepatic triglyceride synthesis and VLDL secretion?
- fenofibrate
- colestipol
- niacin
- ezetimibe
- atorvastatin
Expert Solution
PFA
Archived Solution
You have full access to this solution. To save a copy with all formatting and attachments, use the button below.
For ready-to-submit work, please order a fresh solution below.





